Valuation: Clene Inc.

Market Cap 53.8M 48.07M 44.15M 40.1M 75.3M 5.1B 77.19M 527M 212M 2.69B 202M 198M 8.53B P/E 2026 *
-1.47x
P/E 2027 * -2.22x
Enterprise Value 49.2M 43.96M 40.38M 36.67M 68.86M 4.66B 70.59M 482M 194M 2.46B 185M 181M 7.8B EV / Sales 2026 *
197x
EV / Sales 2027 * 2.39x
Free-Float
83.46%
Yield 2026 *
-
Yield 2027 * -
1 day+4.43%
1 week-5.04%
Current month-1.57%
1 month-7.60%
3 months-27.36%
6 months-38.60%
Current year-35.78%
1 week 3.6
Extreme 3.605
3.99
1 month 3.02
Extreme 3.0152
4.11
Current year 3.02
Extreme 3.0152
8.67
1 year 3.02
Extreme 3.0152
11.59
3 years 2.28
Extreme 2.2801
13.5
5 years 2.28
Extreme 2.2801
122.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 31/03/2013
Chief Tech/Sci/R&D Officer 67 31/12/2012
Director of Finance/CFO 57 31/01/2022
Director TitleAgeSince
Chairman 65 31/10/2015
Director/Board Member 53 31/08/2019
Director/Board Member 49 30/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/09/26 Free

Chief Executive Officer

15,244 0.1186%
16/09/26 Free

Chairman

434,451 3.3813%
16/09/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+4.43%-5.04%-68.53%-53.35% 51.31M
-2.43%-4.38%+40.32%+55.64% 62.23B
+0.61%+1.10%+11.79%+70.22% 54.92B
+0.62%+2.74%+17.68%+103.81% 55.26B
+1.61%-3.30%+22.77%+33.16% 42.59B
-1.74%-3.02%+13.83%+93.17% 41.08B
+3.22%+4.30%+227.37%+776.49% 40.33B
+0.57%+25.47%+102.34%+88.40% 33.12B
-1.09%-0.05%+13.55%+45.35% 32.61B
-4.46%+9.98%-43.92%+320.28% 23.98B
Average +0.13%+2.56%+33.72%+153.32% 38.62B
Weighted average by Cap. -0.21%+2.12%+45.62%+159.76%

Financials

2026 *2027 *
Net sales 249K 223K 205K 186K 349K 23.63M 358K 2.44M 983K 12.47M 936K 916K 39.52M 23.27M 20.79M 19.09M 17.34M 32.56M 2.2B 33.38M 228M 91.68M 1.16B 87.33M 85.46M 3.69B
Net income -34.49M -30.81M -28.3M -25.7M -48.27M -3.27B -49.48M -338M -136M -1.72B -129M -127M -5.47B -31M -27.69M -25.44M -23.1M -43.39M -2.94B -44.48M -304M -122M -1.55B -116M -114M -4.91B
Net Debt -4.6M -4.11M -3.77M -3.43M -6.44M -436M -6.6M -45.06M -18.13M -230M -17.27M -16.9M -729M 1.8M 1.61M 1.48M 1.34M 2.52M 171M 2.58M 17.63M 7.09M 90M 6.76M 6.61M 285M
Projected Income Statement - Annual - Clene Inc.
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
03/11/26 US$3.770 +4.43% 44,308
02/11/26 US$3.610 -5.74% 54,014
30/10/26 US$3.830 -1.79% 47,273
29/10/26 US$3.900 -3.23% 34,254
28/10/26 US$4.030 +1.51% 44,069
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Clene Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.770USD
Average target price
32.20USD
Spread / Average Target
+754.11%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Clene Inc.
  1. Stock Market
  2. Stocks
  3. CLNN Stock